Cybergenetics Corp. v. Institute of Environmental Science and Research

CourtDistrict Court, N.D. Ohio
DecidedSeptember 29, 2020
Docket5:19-cv-01197
StatusUnknown

This text of Cybergenetics Corp. v. Institute of Environmental Science and Research (Cybergenetics Corp. v. Institute of Environmental Science and Research) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cybergenetics Corp. v. Institute of Environmental Science and Research, (N.D. Ohio 2020).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

CYBERGENETICS CORP., ) CASE NO. 5:19-cv-1197 ) ) PLAINTIFF, ) JUDGE SARA LIOI ) vs. ) ) MEMORANDUM OPINION AND ) ORDER INSTITUTE OF ENVIRONMENTAL ) SCIENCE AND RESEARCH, et al., ) ) ) DEFENDANTS. )

Plaintiff Cybergenetics Corp. (“plaintiff”) brought this action on May 24, 2019, alleging that defendants, Institute of Environmental Science and Research and NicheVision Inc. (collectively, “defendants”), infringe U.S. Patent No. 8,898,021 (“‘021 patent”) (Doc. No. 21-1) and U.S. Patent No. 9,708,642 (“‘642 patent”) (Doc. No. 21-2). (See Doc. No. 1 (Complaint).) Plaintiff subsequently filed an amended complaint on October 16, 2019. (Doc. No. 21 [“Am. Compl.”].) Now pending before the Court is a motion to dismiss filed by defendants. (Doc. No. 24 [“Mot.”].) Defendants argue that the asserted claims in the ‘021 patent and the ‘642 patent are not patent eligible under 35 U.S.C. § 101. (Mot. at 5821.) Plaintiff opposes the motion (Doc. No. 29 [“Opp’n”]), and defendants filed a reply. (Doc. No. 30 [“Reply”].)

1 All page number references are to the page identification number generated by the Court’s electronic docketing system. Because the asserted claims of the ‘021 patent and ‘642 patent are ineligible under § 101, as discussed below, defendants’ motion to dismiss is granted. I. BACKGROUND A. Scientific Background The basics of DNA testing, as relevant to this motion, are set forth in the amended complaint. First, a laboratory conducts “PCR amplification” to copy a single DNA sample and

produce billions of similar molecules. (Am. Compl. ¶ 27.) Because PCR amplification “generates a different chain reaction each time DNA copes [sic] are synthesized … repeated amplification of the same [DNA] … will produce different peak heights and patterns compared to the original, naturally occurring DNA fragment.” (Id. ¶ 42.) In short, PCR amplification copies a DNA sample but introduces variation in the copies. (See id. ¶ 43.) Second, a laboratory conducts capillary electrophoresis “to separate the [copied] DNA molecules according to their length” and prevalence in the sample. (Id. ¶¶ 30–31.) This quantifies the DNA sample to transform it into data. (Id. ¶ 31.) Third, under the traditional approach, the laboratory would then set a threshold to “eliminat[e] consideration of possible artifacts and low template DNA” to “simplify the DNA for visual human review[.]” (Id. ¶ 38.)

If there is only one person in the DNA sample, the result of the electrophoresis will easily reveal the genotype of that person. (Id. ¶ 34.) But when there are multiple people in the DNA sample, the analysis becomes more difficult. (Id. ¶ 35.) And when there are multiple unknown contributors in the DNA sample, it becomes even harder. (See id. ¶ 36.)

2 B. Patents-in-Suit The ‘021 and ‘642 patents (“Patents-in-Suit”) are owned by plaintiff and titled “Method and System for DNA Mixture Analysis.” (Id. ¶¶ 12–13.) The Patents-in-Suit recite “computer- based systems and methods for analyzing a DNA sample comprising a mixture of DNA from multiple sources in order to determine a likelihood that a particular person’s DNA is, or is not,

contained within the mixture.” (Id. ¶ 14.) The claimed methods use DNA data produced from PCR amplification and electrophoresis, but then “analyze [the data] to determine information about the composition of the mixed DNA sample.” (Id. ¶ 15.) These methods replace Step 3 of the traditional approach. The Patents-in-Suit call this analysis “deconvolution,” or separating a multi-person DNA sample to identify the individuals in that sample. (Opp’n at 911.) Deconvolution involves calculating the variance of the DNA data produced by PCR amplification and accounting for that variance in subsequent probability calculations. (Am. Compl. ¶¶ 43–47; Opp’n at 911, 914.) Those probability calculations, in turn, predict the identity of an individual in the sample and calculate the likelihood that the prediction is correct. (Am. Compl. ¶ 44.)

II. LEGAL STANDARDS A. Standard of Review A complaint must contain “a short and plain statement of the claim showing that the pleader is entitled to relief[.]” Fed. R. Civ. P. 8(a)(2). Although this pleading standard does not require a great deal of detail, the factual allegations in the complaint “must be enough to raise a right to relief above the speculative level.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555, 127 S. Ct. 1955, 167 L. Ed. 2d 929 (2007) (citing authorities). In other words, “Rule 8(a)(2) still requires a ‘showing,’ rather than a blanket assertion, of entitlement to relief.” Id. at 556 n.3 (criticizing the 3 Twombly dissent’s assertion that the pleading standard of Rule 8 “does not require, or even invite, the pleading of facts”). “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678, 129 S. Ct. 1937, 173 L. Ed. 2d 868 (2009) (quoting Twombly, 550 U.S. at 570). Rule 8

does not “unlock the doors of discovery for a plaintiff armed with nothing more than conclusions.” Id. at 678–79. “While legal conclusions can provide the framework of a complaint, they must be supported by factual allegations. When there are well-pleaded factual allegations, a court should assume their veracity and then determine whether they plausibly give rise to an entitlement to relief.” Id. at 679. “The court need not, however, accept unwarranted factual inferences.” Total Benefits Planning Agency Inc. v. Anthem Blue Cross & Blue Shield, 552 F.3d 430, 434 (6th Cir. 2008) (citing Morgan v. Church’s Fried Chicken, 829 F.2d 10, 12 (6th Cir. 1987)). “Patent eligibility under § 101 is an issue of law,” Intellectual Ventures I LLC v. Capital One Bank (USA), 792 F.3d 1363, 1366 (Fed. Cir. 2015) (citing In re BRCA1– & BRCA2–Based

Hereditary Cancer Test Patent Litig., 774 F.3d 755, 758 (Fed. Cir. 2014)), and can be resolved at the motion to dismiss stage, SAP Am., Inc. v. InvestPic, LLC, 898 F.3d 1161, 1169 (Fed. Cir. 2018), cert. denied, 139 S. Ct. 2747, 204 L. Ed. 2d 1134 (2019); Genetic Techs. Ltd. v. Merial L.L.C., 818 F.3d 1369, 1373 (Fed. Cir. 2016); Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat’l Ass’n, 776 F.3d 1343, 1346, 1351 (2014), cert denied, 136 S. Ct. 119, 193 L. Ed. 2d 208 (2015), so long as “there are no factual allegations that, taken as true, prevent resolving the eligibility question as a matter of law.” Aatrix Software, Inc. v. Green Shades Software, Inc., 882 F.3d 1121, 1125 (Fed. Cir. 2018).

4 B. The Alice Test Important to the Court’s analysis of patent eligibility under § 101 is the Supreme Court’s decision in Alice Corp. Pty. Ltd. v. CLS Bank Int’l., 573 U.S. 208, 134 S. Ct. 2347, 189 L. Ed. 2d 296 (2014). Title 35 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gottschalk v. Benson
409 U.S. 63 (Supreme Court, 1972)
Parker v. Flook
437 U.S. 584 (Supreme Court, 1978)
Diamond v. Diehr
450 U.S. 175 (Supreme Court, 1981)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Carolyn Morgan v. Church's Fried Chicken
829 F.2d 10 (Sixth Circuit, 1987)
Ddr Holdings, LLC v. hotels.com, L.P.
773 F.3d 1245 (Federal Circuit, 2014)
Intellectual Ventures I LLC v. Capital One Bank (USA)
792 F.3d 1363 (Federal Circuit, 2015)
Genetic Technologies Limited v. Merial L.L.C.
818 F.3d 1369 (Federal Circuit, 2016)
Enfish, LLC v. Microsoft Corporation
822 F.3d 1327 (Federal Circuit, 2016)
Electric Power Group, LLC v. Alstom S.A.
830 F.3d 1350 (Federal Circuit, 2016)
McRO, Inc. v. Bandai Namco Games America Inc.
837 F.3d 1299 (Federal Circuit, 2016)
Fairwarning Ip, LLC v. Iatric Systems, Inc.
839 F.3d 1089 (Federal Circuit, 2016)
Thales Visionix Inc. v. United States
850 F.3d 1343 (Federal Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Cybergenetics Corp. v. Institute of Environmental Science and Research, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cybergenetics-corp-v-institute-of-environmental-science-and-research-ohnd-2020.